Silence Therapeutics PLC (SLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silence Therapeutics PLC (SLN) has a cash flow conversion efficiency ratio of -0.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.89 Million) by net assets ($74.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SLN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Silence Therapeutics PLC - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Silence Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Silence Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silence Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Real-Design Intelligent Technology Co. Ltd.
SHE:301135
|
-0.018x |
|
Orion Engineered Carbons SA
F:0OE
|
0.242x |
|
Gaumont SA
PA:GAM
|
0.263x |
|
Guangzhou Seagull Kitchen And Bath Products Co Ltd
SHE:002084
|
0.042x |
|
Transcom Inc
TW:5222
|
0.029x |
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
0.010x |
|
Precious Shipping Public Company Limited
BK:PSL
|
0.038x |
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
0.127x |
Annual Cash Flow Conversion Efficiency for Silence Therapeutics PLC (1995–2024)
The table below shows the annual cash flow conversion efficiency of Silence Therapeutics PLC from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see SLN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $134.02 Million | $-67.64 Million | -0.505x | +71.79% |
| 2023-12-31 | $21.99 Million | $-39.35 Million | -1.789x | +30.77% |
| 2022-12-31 | $22.07 Million | $-57.04 Million | -2.584x | -339.89% |
| 2021-12-31 | $8.53 Million | $9.19 Million | 1.077x | +190.57% |
| 2020-12-31 | $9.06 Million | $-10.78 Million | -1.190x | -1540.18% |
| 2019-12-31 | $20.91 Million | $1.73 Million | 0.083x | +117.28% |
| 2018-12-31 | $35.05 Million | $-16.76 Million | -0.478x | -160.74% |
| 2017-12-31 | $52.35 Million | $-9.60 Million | -0.183x | +1.30% |
| 2016-12-31 | $54.18 Million | $-10.07 Million | -0.186x | -35.99% |
| 2015-12-31 | $60.43 Million | $-8.26 Million | -0.137x | +59.91% |
| 2014-12-31 | $27.76 Million | $-9.46 Million | -0.341x | -39.08% |
| 2013-12-31 | $27.58 Million | $-6.76 Million | -0.245x | +19.02% |
| 2012-12-31 | $16.12 Million | $-4.88 Million | -0.303x | -90.52% |
| 2011-12-31 | $32.18 Million | $-5.11 Million | -0.159x | +51.43% |
| 2010-12-31 | $32.27 Million | $-10.55 Million | -0.327x | +37.45% |
| 2009-12-31 | $8.89 Million | $-4.65 Million | -0.523x | -0.67% |
| 2008-12-31 | $13.44 Million | $-6.98 Million | -0.519x | -139.48% |
| 2007-12-31 | $17.68 Million | $-3.83 Million | -0.217x | +15.48% |
| 2006-12-31 | $15.71 Million | $-4.03 Million | -0.257x | -44.68% |
| 2005-12-31 | $15.69 Million | $-2.78 Million | -0.177x | +83.24% |
| 2004-12-31 | $2.34 Million | $-2.48 Million | -1.058x | -169.58% |
| 2003-12-31 | $5.18 Million | $-2.04 Million | -0.393x | -59.14% |
| 2002-12-31 | $7.46 Million | $-1.84 Million | -0.247x | +3.33% |
| 2001-12-31 | $8.95 Million | $-2.28 Million | -0.255x | +0.60% |
| 2000-12-31 | $11.14 Million | $-2.86 Million | -0.257x | -108.48% |
| 1999-12-31 | $9.21 Million | $-1.13 Million | -0.123x | +77.21% |
| 1998-12-31 | $3.34 Million | $-1.81 Million | -0.540x | -64.85% |
| 1997-12-31 | $4.63 Million | $-1.52 Million | -0.328x | -188.07% |
| 1996-12-31 | $6.39 Million | $-727.00K | -0.114x | +58.72% |
| 1995-12-31 | $2.76 Million | $-761.00K | -0.276x | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more